Skip to main content
OpenTrials
Completed

NCT Number: NCT04172129

Assessment of Implant Fixation and SF-36 for Short Hip-Stems - A Prospective Clinical Study

The primary purpose of this study was to evaluate the implant fixation of the NANOS™ Neck Preserving Hip Stem (OHST Medizintechnik AG, distributed by Smith & Nephew GmbH, Marl, Germany) by measuring the migration of the implant using the model-based roentgen stereophotogrammetric analysis (MBRSA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Orthopädische Klinik der Medizinischen Hochschule Hannover

Hanover, 30625, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject required primary total hip arthroplasty unilateral or bilateral with a diagnosis of primary and secondary coxarthrosis, dysplasia coxarthrosis and post-traumatic necrosis of the femoral head confirmed by x-ray analysis. For bilateral subjects at least three months between surgical procedures were required.
  • Subject was willing to consent to participate in the study and planned to be available for the follow-up examinations.
  • Subject had normal motor function of the lower extremities, documented through clinical examinations and lack of signs of a neurological disease with changed motor function.
  • Subject was 30 to 65 (inclusive) years of age at time of surgery.

Exclusion criteria

  • Subject had previous bone or soft tissue surgery of the affected hip except for arthroscopic surgery.
  • Subject had a local or systemic infection.
  • Subject had previously diagnosed osteoporosis.
  • Subject had a femoral neck angle of >145°.
  • Subject had a femoral neck angle of <125°.
  • Subject had a disease of the cardiovascular system involving particularly reduced load capacity in the everyday life, counting as contraindication of physical stress (American Society of Anaesthesiologists' (ASA) Score 3 or 4).
  • Subject had a documented allergy against elements of the implanted device.
  • Subject had a neurological disease with changed motor function.
  • Subject was pregnant.
  • Subject had a Body Mass Index (BMI) > 30.
  • Subject suffered from alcoholism or addictive disorders.
  • Subject needed a revision hip arthroplasty.
  • Subject had an insufficient command of the language to understand patient information and consent.

Treatment and study plan

Total hip arthroplasty

Device

Primary outcomes

  1. Evaluation of migration pattern of the Nanos stem

    Time frame: 2 years

    Measuring migration used the model-based RSA method

  2. Change in quality of life

    Time frame: 2 years

    Measuring change in quality of life using the Short Form (SF) 36 Mental Component Score

    • Minimum Value: 0 (worst outcome)
    • Maximum Value: 100 (best outcome)

Secondary outcomes

  1. Harris Hip Score

    Time frame: 2 years

    Investigator assessed outcome score Minimum: 0 (worst outcome) Maximum: 100 (best outcome)

  2. University of California, Los Angeles (UCLA) scale

    Time frame: 2 years

    Score rating the patient's current activity level

    • Minimum: 1 (wholly inactive subject)
    • Maximum: 10 (totally active subject)
  3. Pain Visual Analogue Scale

    Time frame: 2 years

    Score representing patient's current pain intensity

    • Minimum: 0 (no pain)
    • Maximum: 100 (very severe pain)
  4. Postel Merle d'Aubigné-Score

    Time frame: 2 years

    Score grading the functional value of the hip

    • Minimum: 0 (worst outcome)
    • Maximum: 6 ( best outcome)

    Grading is done in each of the three dimensions: pain, mobility and ability to walk.

  5. Hip Disability and Ostheoarthritis Outcome Score

    Time frame: 2 years

    Patient reported outcome

    • Minimum: 0 (best outcome)
    • Maximum: 96 (worst outcome)
  6. Radiographic Evaluation

    Time frame: 2 years

    Evaluation of radiographic images regarding implant position, implant fixation, heterotopic ossifications (HO), radiolucencies, osteolysis, atrophy and hypertrophy

  7. Number of adverse events

    Time frame: 2 years

    Collection of adverse events

Sponsors and collaborators

Lead sponsor

Smith & Nephew Orthopaedics AG

Industry

Registry information

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Nov 21, 2019
Registry last updated
Nov 27, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.